CSBio CSBio

X
[{"orgOrder":0,"company":"Neurophth Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Neurophth Therapeutics Announces Presentations at ASGCT and ARVO Annual Meetings","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase II\/ Phase III","country":"CHINA","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"May 2020","url1":"","url2":"","graph1":"Cell and Gene therapy","graph2":"Neurophth Therapeutics"},{"orgOrder":0,"company":"Aurinia Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Aurinia Completes Patient Enrollment Into the AUDREY Phase 2\/3 Clinical Trial of Voclosporin Ophthalmic Solution","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase II\/ Phase III","country":"CANADA","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2020","url1":"","url2":"","graph1":"Small molecule","graph2":"Aurinia Pharmaceuticals"},{"orgOrder":0,"company":"Kodiak Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Kodiak Sciences Announces Upcoming Presentation of KSI-301 Clinical Study Data at American Society of Retina Specialists Meeting","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase II\/ Phase III","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2020","url1":"","url2":"","graph1":"Large molecule","graph2":"Kodiak Sciences"},{"orgOrder":0,"company":"Lonza Group","sponsor":"Kodiak Sciences","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Kodiak, Lonza Sign Long-Term Manufacturing Contract","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase II\/ Phase III","country":"SWITZERLAND","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2020","url1":"","url2":"","graph1":"Large molecule","graph2":"Lonza Group"},{"orgOrder":0,"company":"Tarsus Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Tarsus Pharmaceuticals Welcomes Aziz Mottiwala as Chief Commercial Officer and Relocates to Larger Irvine Headquarters","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase II\/ Phase III","country":"U.S.A","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"August 2020","url1":"","url2":"","graph1":"Undisclosed","graph2":"Tarsus Pharmaceuticals"},{"orgOrder":0,"company":"Neurophth Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Neurophth Therapeutics' Treatment of Leber's Hereditary Optic Neuropathy Gene Therapy NR082 was Granted Orphan Drug Designation by U.S. FDA","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase II\/ Phase III","country":"CHINA","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"September 2020","url1":"","url2":"","graph1":"Cell and Gene therapy","graph2":"Neurophth Therapeutics"},{"orgOrder":0,"company":"Aurinia Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Aurinia Completes Final Patient Treatment in AUDREY Phase 2\/3 Clinical Trial of Voclosporin Ophthalmic Solution for Dry Eye Syndrome","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase II\/ Phase III","country":"CANADA","productType":"Peptide","productStatus":"New Molecular Entity","date":"September 2020","url1":"","url2":"","graph1":"Peptide","graph2":"Aurinia Pharmaceuticals"},{"orgOrder":0,"company":"Azura Ophthalmics","sponsor":"OrbiMed","pharmaFlowCategory":"D","amount":"$20.0 million","upfrontCash":"Undisclosed","newsHeadline":"Azura Ophthalmics Raises US$20 Million for Registration Studies for Treatment of Leading Cause of Dry Eye Disease","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase II\/ Phase III","country":"ISRAEL","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"October 2020","url1":"","url2":"","graph1":"Undisclosed","graph2":"Azura Ophthalmics"},{"orgOrder":0,"company":"Aurinia Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Aurinia Announces Outcome of AUDREY\u2122 Clinical Trial in Dry Eye Syndrome","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase II\/ Phase III","country":"CANADA","productType":"Peptide","productStatus":"New Molecular Entity","date":"November 2020","url1":"","url2":"","graph1":"Peptide","graph2":"Aurinia Pharmaceuticals"},{"orgOrder":0,"company":"Kodiak Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Kodiak Sciences Completes Enrollment of DAZZLE Phase 2b\/3 Pivotal Study of KSI-301 in Patients with Wet Age-Related Macular Degeneration","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase II\/ Phase III","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2020","url1":"","url2":"","graph1":"Large molecule","graph2":"Kodiak Sciences"},{"orgOrder":0,"company":"Azura Ophthalmics","sponsor":"CUREator","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Azura Ophthalmics Secures Grant to Evaluate AZR-MD-001 for Improved Vision Quality Related to Contact Lens Discomfort","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase II\/ Phase III","country":"ISRAEL","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"September 2022","url1":"","url2":"","graph1":"Undisclosed","graph2":"Azura Ophthalmics"},{"orgOrder":0,"company":"Oculis","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Oculis Announces Publication and Presentation of Phase 2 Data Showing Topical OCS-01 Improves Macular Thickness and Visual Acuity in Patients With Diabetic Macular Edema","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase II\/ Phase III","country":"SWITZERLAND","productType":"Small molecule","productStatus":"Approved","date":"September 2022","url1":"","url2":"","graph1":"Small molecule","graph2":"Oculis"},{"orgOrder":0,"company":"Oculis","sponsor":"European Biotech Acquisition Corp","pharmaFlowCategory":"D","amount":"$80.0 million","upfrontCash":"Undisclosed","newsHeadline":"Oculis SA and European Biotech Acquisition Corp Announce Business Combination Agreement to Create Nasdaq-Listed Biopharmaceutical Company Driving Breakthrough Innovations in Ophthalmology","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase II\/ Phase III","country":"SWITZERLAND","productType":"Small molecule","productStatus":"Approved","date":"October 2022","url1":"","url2":"","graph1":"Small molecule","graph2":"Oculis"},{"orgOrder":0,"company":"Allysta Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Allysta Pharmaceuticals, Inc. Announces Completion of Enrollment in Phase 2b\/3 Clinical Trial (OASIS-1) Evaluating the Efficacy and Safety of ALY688 Ophthalmic Solution in Dry Eye Disease","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase II\/ Phase III","country":"U.S.A","productType":"Peptide","productStatus":"New Molecular Entity","date":"November 2022","url1":"","url2":"","graph1":"Peptide","graph2":"Allysta Pharmaceuticals"},{"orgOrder":0,"company":"Azura Ophthalmics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Azura Ophthalmics Announces Positive Results from Phase 2b Clinical Trial of AZR-MD-001 in Meibomian Gland Dysfunction","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase II\/ Phase III","country":"ISRAEL","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2022","url1":"","url2":"","graph1":"Small molecule","graph2":"Azura Ophthalmics"},{"orgOrder":0,"company":"Oculis","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"First Patient Enrolled in LEOPARD, an Investigator-Initiated Trial, with OCS-01 Eye Drops for the Treatment of Cystoid Macular Edema","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase II\/ Phase III","country":"SWITZERLAND","productType":"Small molecule","productStatus":"Approved","date":"August 2023","url1":"","url2":"","graph1":"Small molecule","graph2":"Oculis"},{"orgOrder":0,"company":"Aviceda Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Aviceda Therapeutics Announces Topline Data from Part 1 of the Phase 2\/3 SIGLEC Clinical Trial for AVD-104, Demonstrating Positive Safety and Early Clinical Efficacy in Patients with Geographic Atrophy","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase II\/ Phase III","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2024","url1":"","url2":"","graph1":"Small molecule","graph2":"Aviceda Therapeutics"}]

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

Loading...
Filters Filter
×
FILTER:
filter Company
    filter Sponsor
      filter Country
        filter Product Type
          filter News Type

            Active Filter(s):

            Product Type

            Companies

            Details:

            AVD-104 is a novel small molecule, classical complement pathway modulator. It is currently being evaluated in phase 2/3 clinical trials for the treatment of patients with geographic atrophy secondary to macular degeneration.

            Lead Product(s): AVD-104

            Therapeutic Area: Ophthalmology Product Name: AVD-104

            Highest Development Status: Phase II/ Phase III Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable January 16, 2024

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            OCS-01 is developed using the Optireach® solubilizing technology, a proprietary platform that enables the formulation of drugs as topical eye drop treatment with cystoid macular edema.

            Lead Product(s): Dexamethasone

            Therapeutic Area: Ophthalmology Product Name: OCS-01

            Highest Development Status: Phase II/ Phase III Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable August 02, 2023

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            AZR-MD-001 0.5% meets co-primary efficacy endpoints, making it the first investigational drug to show significant improvements in both signs and symptoms of Meibomian Gland Dysfunction.

            Lead Product(s): AZR-MD-001

            Therapeutic Area: Ophthalmology Product Name: AZR-MD-001

            Highest Development Status: Phase II/ Phase III Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable November 17, 2022

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            ALY688 Ophthalmic Solution contains ALY688, a novel first-in-class peptide with broad anti-inflammatory and corneal epithelial regenerative properties. ALY688 Ophthalmic Solution was well tolerated with a low rate of post-instillation reactions.

            Lead Product(s): ALY688

            Therapeutic Area: Ophthalmology Product Name: ALY688

            Highest Development Status: Phase II/ Phase III Product Type: Peptide

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable November 08, 2022

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            The proceeds expected to support advanced clinical pipeline of multiple innovative products, potentially including the first topical eye-drop for OCS-01 (dexamethasone), the first biologic eye-drop for DED and the first neuroprotective agent for neuro-retina diseases.

            Lead Product(s): Dexamethasone

            Therapeutic Area: Ophthalmology Product Name: OCS-01

            Highest Development Status: Phase II/ Phase III Product Type: Small molecule

            Partner/Sponsor/Collaborator: European Biotech Acquisition Corp

            Deal Size: $80.0 million Upfront Cash: Undisclosed

            Deal Type: Merger October 17, 2022

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            The grant will support Azura’s two-stage study evaluating the safety, tolerability and efficacy of the company’s lead clinical candidate, AZR-MD-001, in patients with contact lens discomfort (CLD) who show evidence of Meibomian gland dysfunction (MGD).

            Lead Product(s): AZR-MD-001

            Therapeutic Area: Ophthalmology Product Name: AZR-MD-001

            Highest Development Status: Phase II/ Phase III Product Type: Undisclosed

            Partner/Sponsor/Collaborator: CUREator

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Funding September 07, 2022

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            Dataset shows that OCS-01 (dexamethasone) eye drops were more effective than vehicle in reducing central macular thickness and improving visual acuity in patients with DME as per the pre-defined criteria for statistical superiority in the study protocol.

            Lead Product(s): Dexamethasone

            Therapeutic Area: Ophthalmology Product Name: OCS-01

            Highest Development Status: Phase II/ Phase III Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable September 06, 2022

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            Kodiak Sciences has concluded recruitment in its DAZZLE pivotal study of KSI-301, Kodiak's anti-VEGF antibody biopolymer conjugate, in patients with neovascular (wet) age-related macular degeneration. Over 550 patients enrolled worldwide.

            Lead Product(s): KSI-301

            Therapeutic Area: Ophthalmology Product Name: KSI-301

            Highest Development Status: Phase II/ Phase III Product Type: Large molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable November 16, 2020

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            Phase 2/3 AUDREY™ clinical study evaluating voclosporin ophthalmic solution (VOS) for the potential treatment of dry eye syndrome (DES) did not achieve statistical significance on the primary endpoint of ≥ 10mm improvement in Schirmer Tear Test (STT) at 4 weeks.

            Lead Product(s): Voclosporin

            Therapeutic Area: Ophthalmology Product Name: ISA247

            Highest Development Status: Phase II/ Phase III Product Type: Peptide

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable November 02, 2020

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            On the back of encouraging Phase 2 data to date proceeds from the funding round will be used to advance Azura’s lead product candidate AZR-MD-001 through a registration study for the treatment of MGD.

            Lead Product(s): AZR-MD-001

            Therapeutic Area: Ophthalmology Product Name: AZR-MD-001

            Highest Development Status: Phase II/ Phase III Product Type: Undisclosed

            Partner/Sponsor/Collaborator: OrbiMed

            Deal Size: $20.0 million Upfront Cash: Undisclosed

            Deal Type: Financing October 22, 2020

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity
            Post Enquiry
            POST ENQUIRY